In the latest trading session, Illumina (ILMN - Free Report) closed at $308.23, marking a -0.95% move from the previous day. This move lagged the S&P 500's daily loss of 0.76%. Meanwhile, the Dow lost 0.82%, and the Nasdaq, a tech-heavy index, lost 0.9%.
Prior to today's trading, shares of the genetic testing tools company had lost 4.72% over the past month. This has lagged the Medical sector's loss of 0.16% and the S&P 500's loss of 1.41% in that time.
Wall Street will be looking for positivity from ILMN as it approaches its next earnings report date. This is expected to be January 29, 2019. On that day, ILMN is projected to report earnings of $1.35 per share, which would represent a year-over-year decline of 6.25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $860.57 million, up 10.61% from the year-ago period.
ILMN's full-year Zacks Consensus Estimates are calling for earnings of $5.72 per share and revenue of $3.33 billion. These results would represent year-over-year changes of +43% and +20.98%, respectively.
Investors should also note any recent changes to analyst estimates for ILMN. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 5.27% higher within the past month. ILMN is holding a Zacks Rank of #2 (Buy) right now.
Investors should also note ILMN's current valuation metrics, including its Forward P/E ratio of 54.45. Its industry sports an average Forward P/E of 26.08, so we one might conclude that ILMN is trading at a premium comparatively.
It is also worth noting that ILMN currently has a PEG ratio of 2.32. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.52 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 92, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ILMN in the coming trading sessions, be sure to utilize Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
In the latest trading session, Illumina (ILMN - Free Report) closed at $308.23, marking a -0.95% move from the previous day. This move lagged the S&P 500's daily loss of 0.76%. Meanwhile, the Dow lost 0.82%, and the Nasdaq, a tech-heavy index, lost 0.9%.
Prior to today's trading, shares of the genetic testing tools company had lost 4.72% over the past month. This has lagged the Medical sector's loss of 0.16% and the S&P 500's loss of 1.41% in that time.
Wall Street will be looking for positivity from ILMN as it approaches its next earnings report date. This is expected to be January 29, 2019. On that day, ILMN is projected to report earnings of $1.35 per share, which would represent a year-over-year decline of 6.25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $860.57 million, up 10.61% from the year-ago period.
ILMN's full-year Zacks Consensus Estimates are calling for earnings of $5.72 per share and revenue of $3.33 billion. These results would represent year-over-year changes of +43% and +20.98%, respectively.
Investors should also note any recent changes to analyst estimates for ILMN. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 5.27% higher within the past month. ILMN is holding a Zacks Rank of #2 (Buy) right now.
Investors should also note ILMN's current valuation metrics, including its Forward P/E ratio of 54.45. Its industry sports an average Forward P/E of 26.08, so we one might conclude that ILMN is trading at a premium comparatively.
It is also worth noting that ILMN currently has a PEG ratio of 2.32. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.52 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 92, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ILMN in the coming trading sessions, be sure to utilize Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ILMN - FREE